Important Safety Info for GLP-1s
See Important Safety Information, including Boxed Warning, about:
Important Safety Information for Wegovy (semaglutide) injection
Warning: Risk of Thyroid C-Cell Tumors
In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is the FDA-approved use of Wegovy?
Wegovy is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or with overweight plus a weight-related condition.
Wegovy is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease and with either obesity or overweight.
Limitations of Use:
Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist
Who should not use Wegovy?
Do not use Wegovy if:
You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to semaglutide or any of the ingredients in Wegovy
How should Wegovy be administered?
You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Blueberry Balance-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.
What should I tell my Blueberry Balance provider before using Wegovy?
Wegovy has certain drug interactions. It’s important to tell your Blueberry Balance-provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Wegovy causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other medications in the GLP-1 medication class, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression, suicidal thoughts, or mental health issues.
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Wegovy should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Wegovy during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Wegovy at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Wegovy was found in the milk of lactating rats. Tell your Blueberry Balance-affiliated provider if you are breastfeeding before you start Wegovy.
Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Wegovy and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Wegovy?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with Wegovy. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Wegovy is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Wegovy may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (hypoglycemia): Wegovy lowers blood glucose. It can cause too low blood sugar in patients who take Wegovy with another glucose control medication, including insulin. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Severe Gastrointestinal Adverse Reactions: Use of Wegovy has been associated with severe gastrointestinal reactions that are sometimes severe.
Serious Allergic Reactions: Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Wegovy causes a delay in gastric emptying. There have been reports of pulmonary aspiration (when food or liquid from the stomach enters the lungs) in people taking GLP-1 medications, including Wegovy, while undergoing surgery requiring sedation, even when instructed to fast before the surgery. If you have a planned major surgery requiring sedation, reach out to your provider for instructions.
Never Share a Pen: Pen-sharing poses a risk of infection.
What are the most common side effects of Wegovy?
Nausea
Diarrhea
Vomiting
Constipation
Dysesthesia (skin sensations)
Stomach pain
Headache
Fatigue
Upset stomach
Dizziness
Bloating
Belching
Low blood sugar in patients with type 2 diabetes
Flatulence
Gastroenteritis
Heartburn
Hair loss
You are encouraged to report negative side effects of prescription products:
Contact Novo Nordisk Inc. at 1-833-934-6891
Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.
Important Safety Information for Saxenda (liraglutide) injection
Warning: Risk of Thyroid C-Cell Tumors
Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether SAXENDA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
SAXENDA is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.
What is the FDA-approved use of Saxenda?
SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:
Adult patients with an initial body mass index (BMI) of:
30 kg/m2 or greater (obese), or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia).
Pediatric patients aged 12 years and older with:
body weight above 60 kg and
an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-offs.
Limitations of Use:
SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.
The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.
The safety and efficacy of SAXENDA in combination with other products intended for weight loss have not been established.
Who should not use Saxenda?
Do not use Saxenda if:
you or any of your family have ever had MTC or if you have MEN 2.
you are allergic to liraglutide or any of the ingredients in Saxenda.
you are pregnant or plan to become pregnant. Saxenda may harm your unborn baby.
How should Saxenda be administered?
You can take Saxenda with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a day. Your Blueberry Balance-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Saxenda as prescribed without discussing with your provider first.
What should I tell my Blueberry Balance provider before using Saxenda?
Saxenda has certain drug interactions. It’s important to tell your Blueberry Balance-provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.
Some medications to watch out for include:
Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Saxenda causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other medications in the GLP-1 medication class, including Ozempic, Saxenda, Wegovy, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:
Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression, suicidal thoughts, or mental health issues.
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
If you are pregnant: Saxenda should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Saxenda during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Saxenda at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Saxenda was found in the milk of lactating rats. Tell your Blueberry Balance-affiliated provider if you are breastfeeding before you start Saxenda.
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
What are the most serious side effects that I or a caregiver should monitor for when taking Saxenda?
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects can occur with Saxenda. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
Thyroid C-Cell Tumors: In mice and rats, liraglutide (the active ingredient in Victoza and Saxenda) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Saxenda is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Saxenda may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (hypoglycemia): Saxenda lowers blood glucose. It can cause too low blood sugar in patients who take Saxenda with another glucose control medication, including insulin. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Severe Gastrointestinal Adverse Reactions: Use of Saxenda has been associated with severe gastrointestinal reactions that are sometimes severe.
Serious Allergic Reactions: Stop using Saxenda right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Saxenda causes a delay in gastric emptying. There have been reports of pulmonary aspiration (when food or liquid from the stomach enters the lungs) in people taking GLP-1 medications, including Saxenda, while undergoing surgery requiring sedation, even when instructed to fast before the surgery. If you have a planned major surgery requiring sedation, reach out to your provider for instructions.
Depression or thoughts of suicide: You should pay attention to any mental changes, especially sudden changes, in your mood, behaviors, thoughts, or feelings. Call your health care provider right away if you have any mental changes that are new, worse, or worry you.
Increased heart rate: Saxenda can increase your heart rate while you are at rest. Your health care provider should check your heart rate while you take Saxenda. Tell your health care professional if you feel your heart racing or pounding in your chest and it lasts for several minutes.
Never Share a Pen: Pen-sharing poses a risk of infection.
What are the most common side effects of Saxenda?
Nausea
Diarrhea
Vomiting
Constipation
Dysesthesia (skin sensations)
Stomach pain
Headache
Fatigue
Upset stomach
Dizziness
Bloating
Belching
Low blood sugar in patients with type 2 diabetes
Flatulence
Gastroenteritis
Heartburn
Hair loss
You are encouraged to report negative side effects of prescription products:
Contact Novo Nordisk Inc. at 1-833-934-6891
Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch
This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

